Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy
Mark Hamilton, Takeshi Sugio, Troy Noordenbos, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 22, pp. 2047-2060
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients
Tobias Tix, Mohammad Alhomoud, Roni Shouval, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 20, pp. 4690-4700
Closed Access | Times Cited: 8
T-Cell Cancer after CAR T-Cell Therapy
Emily Mitchell, George S. Vassiliou
New England Journal of Medicine (2024) Vol. 390, Iss. 22, pp. 2120-2121
Closed Access | Times Cited: 6
CAR T-cell-associated secondary malignancies challenge current pharmacovigilance concepts
Philipp Berg, Gabriele Ruppert‐Seipp, Susanne Müller, et al.
EMBO Molecular Medicine (2025) Vol. 17, Iss. 2, pp. 211-218
Open Access
mRNA‐laden lipid nanoparticle‐enabled humanized CD19 CAR‐T‐cell engineering for the eradication of leukaemic cells
Zhaozhao Chen, Anqi Ren, Yingying Li, et al.
British Journal of Haematology (2025)
Open Access
T cell malignancies after CAR T cell therapy in the DESCAR-T registry
Rémy Duléry, Vincent Guiraud, Sylvain Choquet, et al.
Nature Medicine (2025)
Closed Access
Distinct subtypes of post‐transplant lymphoproliferative disorders: CHIP‐like mutations in early lesions and substantial mutational differences between EBV‐positive and EBV‐negative diffuse large B‐cell lymphomas
Vanesa‐Sindi Ivanova, Thomas Menter, Ningxuan Cui, et al.
British Journal of Haematology (2025)
Closed Access
Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology
Emile M. Youssef, Brandon Fletcher, Dannelle Palmer
Frontiers in Medicine (2025) Vol. 11
Open Access
Chimeric Antigen Receptor-T Cells in the Modern Era of Chronic Lymphocytic Leukemia Treatment
Alycia Hatashima, Mazyar Shadman, Vikram Raghunathan
Cancers (2025) Vol. 17, Iss. 2, pp. 268-268
Open Access
Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context
Valentine Wang, Barbara Savoldo, J. Guimarães, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies
Julie K. Jadlowsky, Elizabeth O. Hexner, Amy Marshall, et al.
Nature Medicine (2025)
Closed Access
The design of retroviral vectors used in the CAR‐T products, risk management, and future perspective
Huifang Yin, Xiaobin Wei
MedComm (2025) Vol. 6, Iss. 2
Open Access
B-Cell-Depleting Immune Therapies as Potential New Treatment Options for Systemic Sclerosis
Gerhard Zugmaier, Matthias Klinger, Marion Subklewe, et al.
Sclerosis (2025) Vol. 3, Iss. 1, pp. 5-5
Open Access
T-cell neoplasias and secondary malignancies after CAR-T cell therapy: current knowledge, risk factors, and implications from CAR-T engineering strategies
Katie Maurer, Caron A. Jacobson
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-9
Closed Access
Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases
Qiaolin Huang, Xiaojian Zhu, Yicheng Zhang
Biomarker Research (2025) Vol. 13, Iss. 1
Open Access
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53
Karlo Perica, Nayan Jain, Michael Scordo, et al.
New England Journal of Medicine (2025) Vol. 392, Iss. 6, pp. 577-583
Closed Access
The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?
Stella Bouziana, Dimitrios Bouzianas
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9518-9518
Open Access | Times Cited: 3
Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation
Madiha Iqbal, Ambuj Kumar, Peter Dreger, et al.
Transplantation and Cellular Therapy (2024) Vol. 30, Iss. 9, pp. 832-843
Open Access | Times Cited: 2
State of the Art on CAR T-Cell Therapies for Onco-Haematological Disorders and Other Conditions
J. Alejandro Madrigal, José C. Crispín
Onco (2024) Vol. 4, Iss. 3, pp. 232-240
Open Access | Times Cited: 1
Advances in cell therapy: progress and challenges in hematological and solid tumors
Claudia D'Avanzo, Franziska Blaeschke, Memnon Lysandrou, et al.
Trends in Pharmacological Sciences (2024)
Open Access | Times Cited: 1
Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy
Shyam A. Patel, Jay Y. Spiegel, Saurabh Dahiya
JAMA Oncology (2024)
Closed Access | Times Cited: 1
Navigating CAR-T cell therapy long-term complications
Céline Gregoire, J. Joseph Melenhorst
Nature Cancer (2024)
Closed Access | Times Cited: 1
Rare Toxicities of CAR T-Cell Therapy: Cardiovascular, Hematopoietic and Other Infrequent Adverse Events

healthbook TIMES Oncology Hematology (2024), Iss. 20
Open Access
Hepatic T cell lymphoma after chimeric antigen receptor T cell therapy for myeloma
Joshua Mehr, Mingyi Chen
eJHaem (2024) Vol. 5, Iss. 6, pp. 1340-1341
Open Access
Sekundärmalignome nach CAR-T-Zelltherapie

DMW - Deutsche Medizinische Wochenschrift (2024) Vol. 149, Iss. 22, pp. 1312-1313
Closed Access
Genetic and immunological features of immune deficiency and dysregulation‐associated lymphoproliferations and lymphomas as a basis for classification
Daan Dierickx, Colm Keane, Yasodha Natkunam
Histopathology (2024)
Closed Access
Page 1 - Next Page

Scroll to top